Literature DB >> 15321884

Access to high cost drugs in Australia.

Christine Y Lu, Ken Williams, Ric Day, Lyn March, Lloyd Sansom, James Bertouch.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15321884      PMCID： PMC514195          DOI： 10.1136/bmj.329.7463.415

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

2.  Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.

Authors:  Stephen J Kerr; Andrea Mant; Fiona E Horn; Kevin McGeechan; Geoffrey P Sayer
Journal:  Med J Aust       Date:  2003-10-20       Impact factor: 7.738
  2 in total
  11 in total

1.  Media influence on Herceptin subsidization in Australia: application of the rule of rescue?

Authors:  Ross Mackenzie; Simon Chapman; Glenn Salkeld; Simon Holding
Journal:  J R Soc Med       Date:  2008-06       Impact factor: 5.344

2.  Recent developments in targeting access to high cost medicines in Australia.

Authors:  Christine Y Lu; Jan Ritchie; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2005-11-23

3.  The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.

Authors:  Christine Y Lu; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2007-03-01

Review 4.  The evolution of Taiwan's National Health Insurance drug reimbursement scheme.

Authors:  Jason C Hsu; Christine Y Lu
Journal:  Daru       Date:  2015-02-10       Impact factor: 3.117

5.  Patient access schemes in Asia-pacific markets: current experience and future potential.

Authors:  Christine Y Lu; Caitlin Lupton; Shana Rakowsky; Zaheer-Ud-Din Babar; Dennis Ross-Degnan; Anita K Wagner
Journal:  J Pharm Policy Pract       Date:  2015-02-16

6.  Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan.

Authors:  Jason C Hsu; Luis A Gonzalez-Gonzalez; Vicky H Lu; Christine Y Lu
Journal:  BMJ Open       Date:  2016-05-27       Impact factor: 2.692

7.  The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia.

Authors:  Christine Y Lu; Jan Ritchie; Ken Williams; Ric Day
Journal:  Aust New Zealand Health Policy       Date:  2007-12-20

8.  Access to high cost medicines in Australia: ethical perspectives.

Authors:  Christine Y Lu; Paul Macneill; Ken Williams; Ric Day
Journal:  Aust New Zealand Health Policy       Date:  2008-05-19

9.  Identifying priority medicines policy issues for New Zealand: a general inductive study.

Authors:  Zaheer-Ud-Din Babar; Susan Francis
Journal:  BMJ Open       Date:  2014-05-28       Impact factor: 2.692

10.  Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study.

Authors:  Jason C Hsu; Christine Y Lu
Journal:  BMJ Open       Date:  2016-06-06       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.